

## Freedom of Information request 183-21

---

### Request & Response

I am analysing the usage of anti-VEFG treatments for eye conditions. I would greatly appreciate if you could answer the below questions:

- For the 4-month period from January to April 2021, how many patients has your trust treated with the following anti-VEGF treatments:

Aflibercept	165
Bevacizumab	0
Brolucizumab	0
Dexamethasone	<5
Fluocinolone acetonide	0
Ranibizumab	<5

- For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Aflibercept	25
Bevacizumab	0
Brolucizumab	0
Dexamethasone	<5
Fluocinolone acetonide	0
Ranibizumab	0

- Within your trust, how many intra-vitreous injections/implants of each the following treatments have been used (for any eye condition) in the four-month period from January to April 2021:

Aflibercept	410
Bevacizumab	0
Brolucizumab	0
Dexamethasone	<5
Fluocinolone acetonide	0
Ranibizumab	6

- If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from January to April 2021 for each of the following conditions:

#### Diabetic Macular Oedema (DMO)

Aflibercept	This information is not recorded, therefore under Section 17 of the FOI(S)A 2002, this information is not held.
Bevacizumab	
Dexamethasone	
Ranibizumab	

## Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

Aflibercept	This information is not recorded, therefore under Section 17 of the FOI(S)A 2002, this information is not held.
Bevacizumab	
Dexamethasone	
Ranibizumab	

As the numbers of events in some areas are very small, and in accordance with the Code of Practice for Official Statistics for any number that is less than five, actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the ISD Statistical Disclosure Control Protocol.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or [foi.enquiries@borders.scot.nhs.uk](mailto:foi.enquiries@borders.scot.nhs.uk).

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **183-21** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.